PRELIMINARY ANALYSIS OF THE PRIME STUDY; A RANDOMIZED CONTROLLED TRIAL COMPARING THE HEPATITIS C CARE CASCADE IN PRIMARY CARE VS. TERTIARY CARE

Wade AJ1,4, Doyle JS1,2, Gane E9, Stedman C10, Draper B1, Iser D2,5, Roberts SK6,7, Kemp W6,7, Petrie D8, Scott N1, Higgs P1,4 11, Agius PA1,4,12, Roney J2, Stothers L5, Thompson AJ3,5*, Hellard ME1,2,4*

1Disease Elimination Program, Burnet Institute, Melbourne, Australia
2Department of Infectious Diseases, The Alfred, Melbourne Australia
3Department of Medicine, University of Melbourne, Melbourne Australia
4School of Population Health and Preventive Medicine, Monash University, Melbourne, Australia
5Department of Gastroenterology, St Vincent’s Hospital, Melbourne, Australia
6Department of Gastroenterology, The Alfred, Melbourne, Australia
7Department of Medicine, Monash University, Melbourne, Australia
8Centre for Health Economics, Monash University, Melbourne, Australia
9New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
10Department of Gastroenterology, Christchurch Hospital, and University of Otago, Christchurch, New Zealand
11Department of Public Health, La Trobe University, Bundoora, Australia
12Judith Lumley Centre, La Trobe University, Melbourne, Australia
* Contributed equally, #presenting author

Background:
In order to eliminate hepatitis C it is essential to increase access to treatment, especially for people who inject drugs (PWID). The Prime Study is an Australasian study that aims to measure the feasibility and efficacy of providing direct acting antivirals (DAAs) in primary care.

Methods:
People with hepatitis C were recruited in primary care and randomized to receive assessment and DAAs in primary care (intervention arm), or the local tertiary hospital (standard of care (SOC) arm). Participants assessed as cirrhotic were ineligible. Study endpoints included key milestones in the care cascade. Participants could exit the study by failing to attend or declining to schedule further appointments. We report descriptive preliminary results from the first 120 participants.

Results:
49% had injected in the last six months. 116 participants were randomized; 59 to the intervention arm and 57 to SOC.
Of 59 participants in the intervention arm; 52 (88%) completed assessment (39 were eligible, 13 were ineligible) and 7 exited the study. Of the 39 eligible participants, 34 commenced DAAs and 5 exited. The treatment rate, excluding ineligible participants, was 34/46 (74%).
32 participants have reached their SVR12 time-point; 15 have completed a test demonstrating SVR12, 1 has an SVR11 and 16 are yet to have a test.
Of 57 participants in the SOC arm; 38 (67%) completed assessment (25 were eligible, 13 were ineligible) and 19 exited the study. Of the 25 eligible participants 17 commenced DAAs and 8 exited. The treatment rate, excluding ineligible participants, was 17/44 (39%). 16 participants have reached their SVR12 time-point; 11 completed a test demonstrating SVR12 and 5 are yet to have a test.
Conclusion:
Preliminary analysis suggests that providing liver assessment and DAAs in primary care may increase treatment uptake, including in PWID – which is key to eliminating hepatitis C.

Figure:

Disclosure of Interest Statement:
The Prime Study is an investigator-initiated study funded by AbbVie. The investigators are responsible for the study design, data collection and analysis, interpretation of data and preparation of manuscripts.

BD, NS, JR – none; AW receives funding for investigator-initiated research from AbbVie; LS reports research funding - Janssen, and speaker - Roche and MSD; MH receives funding for investigator-initiated research - Gilead, BMS and AbbVie; PH receives funding for investigator-initiated research – Gilead, AbbVie; SR reports advisory board member - Gilead, MSD, Bayer, AbbVie and speaker: Gilead, Bayer and PI - Gilead, MSD, Bayer, AbbVie, BMS, Janssen, Arbutus, Assembly Biosciences, Intercept, GSK, NGM pharmaceuticals; WK receives funding from - Gilead, BMS, MSD, AbbVie and PI - DURECT, Arena Pharmaceuticals, MSD; JD receives funding for investigator-initiated research from Gilead, BMS and AbbVie and reports payments to institution for consulting from Merck, BMS, Gilead; DI reports an advisory board member - AbbVie, BMS, MSD, and speaker - AbbVie, BMS, Gilead, MSD, and PI - Gilead, MSD; CS reports advisory board member - AbbVie, MSD, Gilead, and speaker - Gilead, AbbVie, and PI - Gilead, MSD, Abbvie, Janssen, Achillion; AT reports advisory board member - Gilead, AbbVie, Bristol-Myers Squibb (BMS), and Merck, and speaker - Gilead, Merck, BMS, AbbVie, Roche Diagnostics, and PI - Gilead, Merck, AbbVie, BMS, Genfit, Arrowhead, Spring Bank, Sillajen, and research / grant support – Gilead, Merck, BMS, AbbVie, Bayer. EG reports advisory board member - Gilead, Janssen, AbbVie and speaker: Gilead, AbbVie.